Objective: Psoriasis is an inflammatory skin disease with several comorbidities. We aimed to evaluate red blood cell distribution width (RDW), platelet parameters and inflammatory markers in patients on antipsoriasis therapies. Materials and Methods: 94 psoriasis patients and 74 healthy controls were prospectively analyzed. Before and after 8 weeks of different therapies (cal-cipotriol+clobetasol propionate; narrow-band UVB; combined narrow-band UVB and acitretin; infliximab and adalimumab), red blood cell distribution width, platelet parameters, high sensitivity C reactive protein, and erythrocyte sedimentation rate levels were measured. Lipid profile and fasting blood glucose tests were also performed prior the treatment. Psoriasis severity and area index and body mass index were calculated for each patient.
INTRODUCTION
Psoriasis which is a chronic, recurrent skin disease is characterized by systemic inflammation leading to certain autoinflammatory diseases including cardiovascular disease, obesity, insulin resistance, and thromboembolic events [1] . There are many parameters which are elevated in inflammatory diseases and they are accepted as predictors of risk for development of them [2, 3] . The hemogram parameters in routine blood panels have been proposed as one of these markers in systemic inflammation [4] . Red blood cell distribution width (RDW) which is used to differentiate causes of anemia, has been reported to be related with chronic inflammation and has been defined as a prognostic tool in different clinical settings such as pulmonary arterial hypertension, congestive heart failure and coronary heart disease lipid profile including low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C), triglyceride (TG), total cholesterol and FBG tests were also performed prior the treatment. The severity of psoriasis was evaluated by psoriasis severity and area index (PASI). Psoriasis patients were divided into mild (PASI<10) and moderate/severe (PASI ≥10) psoriasis groups. For each group, RDW levels were analyzed. Complete blood count and ESR data, fasting lipid profile and FBG levels were analyzed with flow cytometric, Westergren and spectrophotometric methods, respectively. Hs-CRP was evaluated using nephelometric method. Statistical Analysis All statistical evaluations were performed using Statistical Package for Social Sciences (SPSS) v16.0 for Windows package program. Descriptive analysis was used to summarise the data (mean ±SD or frequencies) as appropriate. In order to compare independent groups with nonparametric data Mann-Whitney U-test and for parametric data independent samples t-test were used. Wilcoxon test and paired sample t test were used to compare the measurements before and after treatment within the same group for data with parametric and non-parametric distributions respectively. Significant p values were accepted when they are ≤0.05 [5] [6] [7] [8] [9] [10] [11] [12] . It has also been detected as a powerful predictor of mortality and morbidity in general population and older adults [13] . And also, platelet parameters including mean platelet volume (MPV), platelet volume distribution width (PDW) and plateletcrit (PCT) have been found to be associated with some inflammatory conditions [14] [15] [16] . The aim of this study was to evaluate the hemogram parameters, erythrocyte sedimentation rate (ESR), high sensitivity C reactive protein (hs-CRP), fasting lipid profile and fasting blood glucose (FBG) levels in patients with psoriasis, and to search for a relationship between hemogram parameters, ESR, hs-CRP and different therapies. We also aimed to determine if RDW might be a new inflammatory marker which shows the severity of psoriasis.
MATERIALS and METHODS
Patients and Procedure After the study protocol was approved by the Hacettepe University School of Medicine ethics committee and the participants provided written informed consent, data were collected from 94 psosiasis patients and 74 healthy controls. The study was conducted at Hacettepe University, School of Medicine, Dermatology Out-Patient Clinic, Ankara, Turkey, between December 2010 and November 2011. Inclusion criteria for psoriasis patients were age ≥18 years, plaque type psoriasis and absence of anemia. Patients who had psoriatic arthritis, had signs of acute or chronic infection or any systemic inflammatory disease and an increase in lesions under treatment were excluded from the study. Patients with a history of any systemic therapy and/or phototherapy for psoriasis within the previous month, any topical treatment within the preceeding two weeks and any systemic anti-inflammatory treatment due to other comorbidities were also excluded. The patient group was divided into five different therapy groups: (1) topical therapy [calcipotriol+clobetasol propionate (n=15)], (2) narrow-band UVB (n=29), (3) combined narrow-band UVB and acitretin (n=11), (4) infliximab (n=24) and (5) adalimumab (n=15), and they had been followed up for 8 weeks under the therapy. The treatment groups were determined according to the comorbidities in the patients, the severity of the disease and their compliance with the treatment. For each patient and control, body mass index (BMI) was calculated before and after treatment. RDW, MPV, PDW, PCT, ESR and hs-CRP levels were measured before and after treatment. Fasting
RESULTS
This prospective study included 94 psoriasis patients (40 males and 54 females) with a mean age of 44.22 ± 14.66 years and 74 healthy controls (32 males and 42 females) with a mean age of 42.02 ± 14.15 years. There were not any significant differences in age or gender between the groups (p=0.385, p=0.929). Mean PASI score at baseline was 9.49 ± 7.04. Patients presented with a significantly higher BMI compared with controls. (Mean of 24.81 ± 3.15 vs 23.79 ± 2,97 kg/m2 ; p=0.035). Baseline laboratory parameters of patients and controls were summarized in Table 1 . Mean RDW, MPV, PDW, PCT, Hb, ESR, hs-CRP, total cholesterol, LDL, TG, FBG levels were higher in the patients than in the controls but the differences were statistically significant only for RDW, hs-CRP, TG and total cholesterol (p=0.020, p=0.049, p=0.005, p=0.049). No any statistically significant difference was found between RDW and severity of psoriasis (p=0.718). Correlation between RDW and baseline PASI scores was depicted in Figure 1 . Analyzing the results of hemogram parameters, hs-CRP and ESR according to therapy groups, no significant differences were observed in mean RDW, MPV, PDW, PCT, hs-CRP and ESR after all five different therapies (p>0.05, for all), as shown in Table 2 . A significant decrease in PASI was detected in all therapy groups (p<0.05, for all). 
DISCUSSION
Psoriasis is a chronic inflammatory autoimmune disease characterized by an excessively aberrant hyperproliferation of keratinocytes. In the complex pathogenesis of psoriasis, T cell-mediated inflammation involving Th1/Th2 homeostasis, the Th17/ Treg balance and the IL-23/Th17 axisis thought to be the main mechanism in degradation of epidermal kinetics. Immunological dysfunction in psoriasis involves the cross-talk between immune cells and cytokines which lead to a chronic systemic inflammation, not limited just only to skin [17] . Numerous studies have investigated the role of several markers in systemic inflammation and in the development of systemic comorbidities in patients with psoriasis [18] [19] [20] [21] [22] . In the literature, it was reported that tumor necrosis factor alpha [23] , interleukin 1 [24] , interleukin 6 [25] , interleukin 23 [25] , intercellular adhesion molecule [26] , adiponectin [27] , leptin [27] , LDL-C [28] , lipoprotein-a [29] , CRP [30] and serum amyloid A [31] have significant correlations between the severity of inflammation and the risk of other comorbidities but there is still a lack of generally accepted marker for assessing the severity of psoriasis and systemic inflammation. RDW which is a quantitative measure of the variability in the size of erythrocytes is mainly used in the differential diagnosis of anemia. Furthermore, recent studies have indicated that RDW may be used also as a marker of inflammation in many diseases such as cardiovascular disease [5, 9] , pulmonary hypertension [8] , rheumatoid arthritis [10] , inflammatory bowel disease [6, 7, 12] , celiac disease [32] and metabolic syndrome [33] . It has been reviewed that chronic inflammation results in disorders of iron metabolism and decreases both production of and bone marrow responsiveness to erythropoietin, resulting in impaired hematopoiesis and increased RDW levels [34] . Complete blood count which includes RDW is one of the most common diagnostic tests in hospital admissions and it is easy, rapid and inexpensive to perform; as such, we think RDW might be a practical marker to assess the systemic inflammation and severity in psoriasis. However, in our study, we did not find any correlation between RDW and PASI. And also, we showed that different therapies did not influence RDW. Literature review has yielded some studies evaluating RDW in psoriasis patients. Firstly, Kim et al. [35] conducted a retrospective study on 261 psoriasis patients and 102 healthy controls and they found that the mean RDW was significantly higher in patients with psoriasis compared with healthy controls but RDW was not correlated with PASI. In their study, they had some limitations such as not excluding patients with anemia or other inflammatory diseases and including patients on methotrexate therapy which may cause to anemia. In another study of Dogan et al. [36] , it was also showed that psoriatic inflammation can simultaneously cause RDW elevation. Like the study of Kim et al. [35] and Dogan et al. [36] , our findings supply the positive association between RDW and psoriasis. We did not find any change in RDW levels on the 8th week of antipsoriasis therapies. Balavi et al. [37] found a decrease in RDW levels on the 3th month of antipsoriasis therapy. Based on their studies, we think that we need to monitor patients longer to determine the decrease in RDW level. We disigned this prospective study excluding the possible confounding factors such as anemia and psoriatic arthritis. And also, we excluded patients with a history of acute or chronic infection or any systemic inflammatory disease. As these factors might have an influence on RDW, future studies should consider these confounders, as well, while investigating the asscociation between RDW and psoriasis.
Evaluating the results of our study, we concluded that MPV, PDW and PCT that are parameters used to indicate platelet size, distribution of platelet size, the rate of platelet count to blood and platelet activity are not sensitive or spesific enough to predict the severity of inflammation in psoriasis patients. We think that, new studies are needed to show the role of platelets in psoriasis.
In this study, we compared inflammatory markers as ESR and hs-CRP between psoriasis patients and controls, and we analysed the effects of different therapies on these markers over a period of 8 weeks. We found that mean hs-CRP and ESR levels were higher in psoriasis patients than in the controls and the difference was significant for hs-CRP, RDW: Red blood cell distribution width, MPV: Mean platelet volume, PDW: Platelet volume distribution width, PCT: Plateletcrit, hs-CRP: High sensitivity C reactive protein, ESR: Erythrocyte sedimentation rate, PASI: Psoriasis area and severity index but not for ESR (p=0.02, for hs-CRP and p=0.081, for ESR). Several studies indicating increased CRP levels in psoriasis patients suggest that systemic inflammation provides a predisposition for development of cardiovascular diseases and other comorbidities [38, 39] . Based on these results, we may conclude that screening the patients for hs-CRP may be useful to assess the risk of other comorbidities in psoriasis. In this study, not any statistically significant decrease was observed in hs-CRP and ESR levels under five different therapies, although all therapy groups experienced clinical improvements and statistically significant reductions in PASI scores. Our results seem to show that antipsoriasis therapies do not have any effect on systemic inflammation parameters in the blood. However, we did not follow-up the patients for a long time, we evaluated the parameters on the 8th week of therapies. Eight weeks therapy may not be a sufficient time to evaluate the decrease in systemic inflammation parameters for psoriasis.
In the literature, there are several studies reporting close association between psoriasis and cardiovascular disease, obesity, diabetes, hypertension, dyslipidemia, metabolic syndrome, nonalcoholic fatty liver disease, cancer, anxiety and depression, and inflammatory bowel disease [40] . In our study, we found a significantly higher mean BMI in patients compared with controls. In the literature, Ferguson et al. [41] reported the risk of obesity in psoriasis patients lastly. In another population-based prospective cohort study of Han et. al [42] , subjects with BMI of more than 30 were found to have a higher risk of psoriasis compared with the BMI 18.5-23 group. Our results and the literature support the risk of obesity in psoriasis. Obesity is a chronic disease and has also systemic inflammatory effects [43] . Adipocytokines and proinflammatory cytokines produced by the truncal adipose tissue have been found to be associated with insulin resistance also [44] . Pereira et al. [45] recently found a significant association between psoriasis and insulin resistance with an odds ratio of 2.63 of abnormal glucose homeostasis in psoriasis patients compared to controls. In the present study, we did not find any correlation between FBG and psoriasis but we think that evaluating FBG levels only is not enough to determine the risk of insulin resistance in patients with psoriasis. Further tests should be performed to show this association. Dyslipidemia was reported to be another comorbidity in psoriasis. The cytokines IL-1, IL-6, and TNFalpha that are involved in the pathogenesis of psoriasis may alter the function of hepatocytes resulting in dyslipidemia [39] . The present findings show that LDL-C, TG and total cholesterol levels were higher and HDL-C was lower in patients with psoriasis than in the controls. Our results confirm that psoriatic patients require through lipid examinations. The limitations of our study are the relatively small samples of therapy groups and short duration of follow-up. Additional studies, with larger sample sizes and longer follow-up periods, are required to more clearly understand the correlations between antipsoriasis therapy and serum inflammatory markers.
CONCLUSION
In conclusion, the present study indicates that TG, total cholesterol and BMI are higher in psoriasis patients and they should be screened for dyslipidemia and obesity. RDW and hs-CRP might be useful to detect systemic inflammation in psoriasis but platelet activating parameters and ESR do not show any changes in psoriasis. Antipsoriasis therapies do not seem to affect hemogram parameters including RDW, MPV, PDW, PCT and also, hs-CRP and ESR levels. Further studies are needed to elucidate the relationship between RDW and psoriasis severity.
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